What to know about the latest HRT thinking

New guidelines for the use of hormone replacement therapy (HRT) have been released in the US.

In its updated position statement, the North American Menopause Society reaffirms HRT’s  efficacy for managing vasomotor symptoms (VMS) and genitourinary syndrome of menopause (GSM).

While these guidelines pertain to the US, they remain relevant locally. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists is due to review its guidelines in July next year.

Here’s what the US guidelines say:

Vasomotor symptoms

  • HRT is the most effective treatment for VMS.
  • It has the most favorable benefit–risk ratio in women under 60 or within 10 years of the onset of menopause.
  • For women aged 60-plus or more than 10 years from the onset